These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1393 related articles for article (PubMed ID: 17966182)

  • 1. Treatment of lentigo maligna with imiquimod 5% cream.
    Hopson B; Richey D; Sajben FP
    J Drugs Dermatol; 2007 Oct; 6(10):1037-40. PubMed ID: 17966182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Videodermatoscopy of lentigo maligna treated with imiquimod.
    Micali G; Lacarrubba F; Nardone B; Nasca MR
    J Drugs Dermatol; 2008 Nov; 7(11):1077-80. PubMed ID: 19110742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
    Powell AM; Robson AM; Russell-Jones R; Barlow RJ
    Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
    Swetter SM; Chen FW; Kim DD; Egbert BM
    J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
    Michalopoulos P; Yawalkar N; Brönnimann M; Kappeler A; Braathen LR
    Br J Dermatol; 2004 Oct; 151(4):903-6. PubMed ID: 15491436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Topical imiquimod as palliative therapy for extensive lentigo maligna on the cheek].
    Cheikhrouhou H; Pouaha J; Claeys A; Truchetet F
    Ann Dermatol Venereol; 2010 Feb; 137(2):142-4. PubMed ID: 20171439
    [No Abstract]   [Full Text] [Related]  

  • 8. A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
    Fleming CJ; Bryden AM; Evans A; Dawe RS; Ibbotson SH
    Br J Dermatol; 2004 Aug; 151(2):485-8. PubMed ID: 15327559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical imiquimod immunotherapy in the management of lentigo maligna.
    Powell AM; Russell-Jones R; Barlow RJ
    Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
    Powell AM; Russell-Jones R
    J Am Acad Dermatol; 2004 May; 50(5):792-6. PubMed ID: 15097969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance].
    Lorentzen HF; Weismann K
    Ugeskr Laeger; 2005 Sep; 167(39):3696-7. PubMed ID: 16219219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical 5% imiquimod in the treatment of lentigo maligna.
    Wong JG; Toole JW; Demers AA; Musto G; Wiseman MC
    J Cutan Med Surg; 2012; 16(4):245-9. PubMed ID: 22784516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lentigo maligna treated with 5% imiquimod cream].
    Martín T; Ojeda A; Martínez S; Vera A
    Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of lentigo maligna with imiquimod before staged excision.
    Cotter MA; McKenna JK; Bowen GM
    Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periocular lentigo maligna treated with imiquimod.
    O'Neill J; Ayers D; Kenealy J
    J Dermatolog Treat; 2011 Apr; 22(2):109-12. PubMed ID: 20666668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream.
    van Meurs T; van Doorn R; Kirtschig G
    Dermatol Surg; 2007 May; 33(5):623-6; discussion 626-7. PubMed ID: 17451589
    [No Abstract]   [Full Text] [Related]  

  • 18. Usefulness of dermoscopy to monitor clinical efficacy of imiquimod treatment for lentigo maligna.
    Micantonio T; Fargnoli MC; Peris K
    Arch Dermatol; 2006 Apr; 142(4):530-1. PubMed ID: 16618884
    [No Abstract]   [Full Text] [Related]  

  • 19. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
    Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
    Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
    J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.